Serum anti-ARS antibody levels were significantly higher in rheumatoid arthritis patients with interstitial lung disease compared to those without chronic lung disease (16.3 vs 7.4; p=5.58×10−12).
Observational
Are serum anti-ARS antibody levels associated with interstitial lung disease in patients with rheumatoid arthritis?
Serum anti-ARS antibodies are elevated in rheumatoid arthritis patients with interstitial lung disease and, when combined with clinical factors, may serve as a biomarker for ILD.
Absolute Event Rate: 16.3% vs 7.4%
p-value: p=5.58 × 10−12
Objectives: A common complication in patients with rheumatoid arthritis (RA) is interstitial lung disease (ILD). Antibodies (Abs) to anti-aminoacyl-transfer ribonucleic acid synthetase (ARS) are linked to ILD in patients with idiopathic inflammatory myopathies (IIM). There have been limited studies of anti-ARS Abs in RA. In this study, we examined anti-ARS Abs in ILD in patients with RA. Methods: Anti-ARS Abs in serum from patients with RA were measured. Results: There were higher anti-ARS Ab levels in RA patients with ILD (mean ± SDM, 16.3 ± 32.3 vs. 7.4 ± 7.0 (Index), p = 5.58 × 10−12), usual interstitial pneumonia (14.4 ± 24.4 vs. 7.4 ± 7.0 Index, p = 3.14 × 10−12), and nonspecific interstitial pneumonia (17.9 ± 37.7 vs. 7.4 ± 7.0 (Index), p = 5.07 × 10−5) compared with patients without chronic lung disease. The area under the curve (AUC) of the receiver operating characteristic curve for anti-ARS Ab was too low to allow for discrimination among RA patients with/without chronic lung disease (0.608, 95% confidence interval (CI) 0.560–0.655, p = 8.69 × 10−6). Multiple logistic regression analyses of age, smoking status, anti-ARS Abs, as well as Steinbrocker stage generated an ARS-index with a high AUC value (0.707, 95%CI 0.662–0.752, p = 2.20 × 10−19). Conclusions: Anti-ARS Abs are related to ILD pathogenesis in RA and may be a biomarker for ILD.
Oka et al. (Sun,) conducted a observational in Rheumatoid arthritis with interstitial lung disease. Anti-ARS antibodies vs. Patients without chronic lung disease was evaluated on Anti-ARS Ab levels (p=5.58 × 10−12). Serum anti-ARS antibody levels were significantly higher in rheumatoid arthritis patients with interstitial lung disease compared to those without chronic lung disease (16.3 vs 7.4; p=5.58×10−12).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: